MedTrace Logo

Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS

NCT06587698 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2024-09-19

No results posted yet for this study

Summary

This study will be carried out under the guidance of professional doctor, patients with PCOS will be treated with Sitagliptin or BeiDouGen capsule or both two to assess their ovarian function and reproductive outcomes, and compare the effect of different treatment methods, which will provide the basis for PCOS intervention strategy and related research

Conditions

  • Polycystic Ovarian Syndrome

Interventions

DRUG

Sitagliptin

100 mg QD for 3 month

DRUG

BeiDouGen

60 mg BID for 3 month

DRUG

Sitagliptin+BeiDouGen

100 mg Sitagliptin QD plus BeiDouGen 60 mg BID for 3 month

Sponsors & Collaborators

  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • Jie Qiao · the third hospital of peking universry

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-21
Primary Completion
2028-07-01
Completion
2029-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06587698 on ClinicalTrials.gov